Opioid Induced Side Effects Treatment Market Highlights 2018 – Industry Development by 2026, Detailed Analysis Research Report

Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group.

For In depth Information Get Sample Copy of this Report at: https://bit.ly/2H9f3EZ

However, opioid drugs use in noncancerous patients is contentious, mostly related with chronic pain treatment and the major reason behind it the psychological addiction which may occur due to the continuous use of opioid drugs also other side effects may induce due to use of opioid drugs are nausea, sedation, constipation, dizziness, vomiting, sweating, headache, respiratory depression and physical dependence, among these constipation is the mostly observed problem occurs in 40% to 95% of patients treated with opioid. Also, some side effects such as delirium and drowsiness depends on dose and they can be avoided by reducing the amount of dose.

Market Taxonomy:

Opioid induced side effects treatment market taxonomy:
By Dosage Form of Drug
Solid
Semi-Solid
Liquid

By Geography
North America
Europe
APAC
Latin America
Middle East
Africa

Increase in prevalence of chronic disease and cancer cases with raised use of prescription based opioids will favor the growth of opioid induced side effects treatment market in the near future

North America accounts for the major market share of opioid induced side effects treatment market, as U.S. is the biggest consumer for prescription based opioids. As per NIDA in 2013, out of the globe U.S. accounted around 100 percent in case of hydrocodone for example – Lortab, Norco and Vicodin, and 81% for oxycodone for example Endocet and Percocet. Also, as per American Society of Addiction Medicine (ASAM), drug overdose is the leading cause of death in U.S. and prescription opioids is the leading factor behind it. In 2015, 12,990 deaths were related with prescription based pain relievers.

The growth in opioid induced side effects treatment market is expected high in North America followed by Europe and APAC region. As per the data published by UNODC in 2012, the APAC and Africa region are the emerging markets for raw opium which could feed to increase opioid consumption and support the growth of opioid induced side effects treatment industry in near the future. Furthermore, only 20% of opioid users received treatment against their drug dependence and treatment demand is growing in Asia and Europe region. The South America has shown negligible growth in demand for treatment against opioid drug dependency.

As very few percentage of opioid users received treatment and more are looking for the treatment options in emerging economies as well as in developed region provides scope for the companies to develop and make available the treatment against opioid induced side effects. This in turn is projected to favor the gain in traction for opioid induced side effects treatment market.

Some major medications in opioid induced side-effects treatment market are risperidone, methylphenidate, cetirizine, fexofenadine. In 2014, Naloxone hydrochloride injection (Evzio), a prescription treatment against opioid overdose side effects received approval by U.S. Food and Drug Administration (FDA). It is the first auto-injector designed to use outside of the health care setting which can be used by care taker to treat person have had overdose of opioids.

Request Customization: https://bit.ly/2EyP1cq

Key Players:

Some of the key players in the global opioid induced side effects treatment market are :
Shionogi & Co., Ltd.
Cubist Pharmaceuticals, Inc.
AIKO Biotechnology, Inc.
SLA Pharma AG
Progenics Pharmaceuticals Inc.
AstraZeneca plc.

Browse Research Report At: https://bit.ly/2T3te5x

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com
https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.